Skip to content
AnalystLens

BridgeBio Pharma 8-K Report, Financial Results (Feb 24, 2026)

Reports
Earnings & Results·Exhibits & Filings
Filing Date
Filed February 24, 2026
Period End
February 24, 2026
Security
BBIO
In the record · 2019–202610-K710-Q238-K107

BBIO filed 7 annual reports (10-K), 23 quarterly reports (10-Q) and 107 current reports (8-K) between 2019 and 2026.

  1. Leadership change8-K · Feb ’20Feb ’20
  2. Leadership change8-K · Oct ’21Oct ’21
  3. Material agreement8-K · Sep ’23Sep ’23
  4. Material agreement8-K · Jul ’25Jul ’25

Summary

Summary of the 8-K filed February 24, 2026. Cited figures are marked; the original filing is the authoritative source.

BridgeBio Pharma, Inc. (Nasdaq: BBIO) reported financial results for the fourth quarter and full year ended December 31, 2025 in a press release furnished as Exhibit 99.1 to this Form 8-K.

Total revenues, net were $154.2 milliona for the fourth quarter and $502.1 million for the full year, led by U.S. Attruby net product revenue of $146.0 million in the quarter and $362.4 million for the year. Net loss attributable to common stockholders of BridgeBio was $192.9 million for the quarter and $724.9 million for the year, or $(1.00) and $(3.78) per share. Total operating costs and expenses for the full year were $1.0 billion, with selling, general and administrative expenses of $531.2 million reflecting commercial launch investments for Attruby.

Cash, cash equivalents and marketable securities totaled $587.5 millionb as of December 31, 2025, down from $681.1 million a year earlier. The company stated that net cash used in operating activities was $445.9 million for 2025. In January 2026, BridgeBio completed issuance of $632.5 million aggregate principal amount of Convertible Senior Notes due 2033, which it describes as part of a strategy to lower interest expense, reduce dilution and extend debt maturity.

Pipeline progress was the main focus of the update. The company reported positive Phase 3 results for BBP-418 (FORTIFY interim analysis), encaleret (CALIBRATE) and infigratinib (PROPEL 3), and plans NDA submissions for BBP-418 and encaleret in the first half of 2026 and for infigratinib in the second half of 2026. The company also noted that BBP-418, BBP-812 and infigratinib may be eligible for a Rare Pediatric Disease Priority Review Voucher upon approval.

Key Highlights

  1. Q4 2025 total revenues, net of $154.2 million, versus $5.9 million in Q4 2024; full-year 2025 revenues of $502.1 million versus $221.9 million in 2024.
  2. Q4 2025 net product revenue from Attruby was $146.0 million; full-year 2025 net product revenue was $362.4 million.
  3. Q4 2025 net loss attributable to common stockholders of BridgeBio was $192.9 million ($1.00 per share); full-year net loss was $724.9 million ($3.78 per share).
  4. Selling, general and administrative expenses rose to $531.2 million for full-year 2025 from $288.9 million, largely reflecting commercial launch investments for Attruby.
  5. Cash, cash equivalents and marketable securities were $587.5 million at December 31, 2025; net cash used in operating activities was $445.9 million for 2025.
  6. In January 2026, the company issued $632.5 million of 2033 Convertible Senior Notes, which it describes as aimed at lowering interest expense, reducing dilution and extending debt maturity.
  7. Regulatory milestones: NDA submissions planned in 1H 2026 for BBP-418 and encaleret, and in 2H 2026 for infigratinib, with U.S. launches anticipated from late 2026 into 2027.

Frequently Asked Questions

  1. How much revenue did BridgeBio generate in the fourth quarter and full year 2025?

    Total revenues, net were $154.2 million in the fourth quarter of 2025 and $502.1 million for the full year. Net product revenue from Attruby accounted for $146.0 million of the quarter's total and $362.4 million of the full-year total.

  2. What was the net loss and how did it compare with the prior year?

    The net loss attributable to common stockholders of BridgeBio was $192.9 million for the fourth quarter and $724.9 million for the full year 2025, compared with $265.1 million and $535.8 million in the same periods of 2024. Net loss per share was $1.00 for the quarter and $3.78 for the year.

  3. What is BridgeBio's cash position and what drove the change?

    Cash, cash equivalents and marketable securities totaled $587.5 million at December 31, 2025, compared with $681.1 million a year earlier. The company attributed the decrease mainly to net cash used in operating activities of $445.9 million, the repayment of its previous term loan of $459.0 million, and a $48.3 million stock repurchase, partially offset by net proceeds from its 2031 Notes and a royalty financing with HealthCare Royalty and Blue Owl Capital.

  4. What are the company's key pipeline catalysts for 2026?

    The company plans to submit NDAs to the FDA for BBP-418 (LGMD2I/R9) and encaleret (ADH1) in the first half of 2026, and for infigratinib (achondroplasia) in the second half of 2026. The Phase 2 data for infigratinib in hypochondroplasia is expected in the second half of 2026, and more Attruby data will be shared at the ACC meeting in March 2026.

  5. What did the company say about its January 2026 convertible notes offering?

    BridgeBio completed issuance of $632.5 million aggregate principal amount of Convertible Senior Notes due 2033 in January 2026. The company said this transaction is part of its strategy to lower interest expense, reduce dilution and significantly extend debt maturity.